Liquid chromatography - Mass spectrometry-based parallel metabolic profiling of human and mouse model serum reveals putative biomarkers associated with the progression of nonalcoholic fatty liver disease

Journal of Proteome Research

Volumn 9, Issue 9, 2010, Pages 4501-4512

  Barr, Jonathan ^a,e,k   Vázquez Chantada, Mercedes ^b   Alonso, Cristina ^a   Pérez Cormenzana, Miriam ^b   Mayo, Rebeca ^a   Galán, Asier ^c   Caballería, Juan ^d   Martín Duce, Antonio ^d   Tran, Albert ^e,f,g   Wagner, Conrad ^h,i   Luka, Zigmund ^h   Lu, Shelly C ^j   Castro, Azucena ^a   Le Marchand Brustel, Yannick ^e,f,g   Martínez Chantar, M Luz ^a   Veyrie, Nicolas ^a   Clément, Karine ^a   Tordjman, Joan ^a   Gual, Philippe ^e,f,g   Mato, José M ^b  

^a OWL Genomics   (Spain)

^b CIC BIOGUNE   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d UNIVERSITY OF ALCALÁ   (Spain)

^e INSERM   (France)

^f UNIVERSITÉ CÔTE D'AZUR   (France)

^g UNIVERSITY HOSPITAL OF NICE   (France)

^h VANDERBILT UNIVERSITY   (United States)

ⁱ Affairs Medical Center   (United States)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^k SORBONNE UNIVERSITÉ   (France)

more..

Author keywords

biomarkers; metabolomics; NAFLD; NASH; steatosis

Indexed keywords

ARACHIDONIC ACID; BIOLOGICAL MARKER; GLUTAMIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; MALE; MASS SPECTROMETRY; METABOLOMICS; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; STEATOSIS; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY;

ANIMALS; BIOLOGICAL MARKERS; CHROMATOGRAPHY, LIQUID; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; FATTY LIVER; GLYCINE N-METHYLTRANSFERASE; HUMANS; LIPID METABOLISM; MALE; MASS SPECTROMETRY; METABOLOMICS; MICE; MICE, KNOCKOUT; MULTIVARIATE ANALYSIS; PRINCIPAL COMPONENT ANALYSIS;

ANIMALIA;

EID: 77956326416     PISSN: 15353893     EISSN: 15353907     Source Type: Journal    
DOI: 10.1021/pr1002593     Document Type: Article

References (95)

1. World Health Organization. Obesity and Overweight; In Geneva, 2006; Factsheet No. 3011.
2. Reid, A. E. Nonalcoholic steatohepatitis Gastroenterology 2001, 121 (3) 710-23
3. Clark, J. M.; Diehl, A. M. Defining nonalcoholic fatty liver disease: implications for epidemiologic studies Gastroenterology 2003, 124 (1) 248-50
4. Marchesini, G.; Bugianesi, E.; Forlani, G.; Cerrelli, F.; Lenzi, M.; Manini, R.; Natale, S.; Vanni, E.; Villanova, N.; Melchionda, N.; Rizzetto, M. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome Hepatology 2003, 37 (4) 917-23
5. Adams, L. A.; Lindor, K. D. Nonalcoholic fatty liver disease Ann. Epidemiol. 2007, 17 (11) 863-9
6. Angulo, P. Obesity and nonalcoholic fatty liver disease Nutr. Rev. 2007, 65 (6 Pt 2) S57-63
7. Parekh, S.; Anania, F. A. Abnormal lipid and glucose metabolism in obesity: implications for nonalcoholic fatty liver disease Gastroenterology 2007, 132 (6) 2191-207
8. Matteoni, C. A.; Younossi, Z. M.; Gramlich, T.; Boparai, N.; Liu, Y. C.; McCullough, A. J. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 1999, 116 (6) 1413-9
9. Caldwell, S. H.; Crespo, D. M.; Kang, H. S.; Al-Osaimi, A. M. Obesity and hepatocellular carcinoma Gastroenterology 2004, 127 (5) S97-103
10. El-Serag, H. B. Hepatocellular carcinoma: recent trends in the United States Gastroenterology 2004, 127 (5) S27-34
11. Malhi, H.; Gores, G. J. Molecular mechanisms of lipotoxicity in nonalcoholic fatty liver disease Semin. Liver Dis. 2008, 28 (4) 360-9
12. Mato, J. M.; Lu, S. C. Role of S-adenosyl-L-methionine in liver health and injury Hepatology 2007, 45 (5) 1306-12
13. Mato, J. M.; Martinez-Chantar, M. L.; Lu, S. C. Methionine metabolism and liver disease Annu. Rev. Nutr. 2008, 28, 273-93
14. Tordjman, J.; Poitou, C.; Hugol, D.; Bouillot, J. L.; Basdevant, A.; Bedossa, P.; Guerre-Millo, M.; Clement, K. Association between omental adipose tissue macrophages and liver histopathology in morbid obesity: influence of glycemic status J. Hepatol. 2009, 51 (2) 354-62
15. Farrell, G. C.; Larter, C. Z. Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 2006, 43 (2) S99-S112
16. Dixon, J. B.; Bhathal, P. S.; Hughes, N. R.; O'Brien, P. E. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss Hepatology 2004, 39 (6) 1647-54
17. Klein, S.; Mittendorfer, B.; Eagon, J. C.; Patterson, B.; Grant, L.; Feirt, N.; Seki, E.; Brenner, D.; Korenblat, K.; McCrea, J. Gastric bypass surgery improves metabolic and hepatic abnormalities associated with nonalcoholic fatty liver disease Gastroenterology 2006, 130 (6) 1564-72
18. Wanless, I. R.; Lentz, J. S. Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors Hepatology 1990, 12 (5) 1106-10
19. Marchesini, G.; Brizi, M.; Morselli-Labate, A. M.; Bianchi, G.; Bugianesi, E.; McCullough, A. J.; Forlani, G.; Melchionda, N. Association of nonalcoholic fatty liver disease with insulin resistance Am. J. Med. 1999, 107 (5) 450-5
20. Marra, F.; Gastaldelli, A.; Svegliati Baroni, G.; Tell, G.; Tiribelli, C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis Trends Mol. Med. 2008, 14 (2) 72-81
21. Oh, M. K.; Winn, J.; Poordad, F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease Aliment Pharmacol. Ther. 2008, 28 (5) 503-22
22. Kleiner, D. E.; Brunt, E. M.; Van Natta, M.; Behling, C.; Contos, M. J.; Cummings, O. W.; Ferrell, L. D.; Liu, Y. C.; Torbenson, M. S.; Unalp-Arida, A.; Yeh, M.; McCullough, A. J.; Sanyal, A. J. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 2005, 41 (6) 1313-21
23. Ratziu, V.; Charlotte, F.; Heurtier, A.; Gombert, S.; Giral, P.; Bruckert, E.; Grimaldi, A.; Capron, F.; Poynard, T. Sampling variability of liver biopsy in nonalcoholic fatty liver disease Gastroenterology 2005, 128 (7) 1898-906
24. Castera, L.; Foucher, J.; Bertet, J.; Couzigou, P.; de Ledinghen, V. FibroScan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases Hepatology 2006, 43 (2) 373-4; author reply 375-6
25. Kotronen, A.; Peltonen, M.; Hakkarainen, A.; Sevastianova, K.; Bergholm, R.; Johansson, L. M.; Lundbom, N.; Rissanen, A.; Ridderstrale, M.; Groop, L.; Orho-Melander, M.; Yki-Jarvinen, H. Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors Gastroenterology 2009, 137 (3) 865-72
26. Poynard, T, I.-B. F.; Munteanu, M.; Messous, D.; Myers, R. P.; Thabut, D.; Ratziu, V.; Mercadier, A.; Benhamou, Y; Hainque, B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C Comp. Hepatol. 2004, 4, 10-23
27. Imbert-Bismut, F.; Messous, D.; Thibault, V.; Myers, R. B.; Piton, A.; Thabut, D.; Devers, L.; Hainque, B.; Mercadier, A.; Poynard, T. Intra-laboratory analytical variability of biochemical markers of fibrosis (Fibrotest) and activity (Actitest) and reference ranges in healthy blood donors Clin. Chem. Lab. Med. 2004, 42 (3) 323-33
28. Poynard, T.; Ratziu, V.; Naveau, S.; Thabut, D.; Charlotte, F.; Messous, D.; Capron, D.; Abella, A.; Massard, J.; Ngo, Y.; Munteanu, M.; Mercadier, A.; Manns, M.; Albrecht, J. The diagnostic value of biomarkers (SteatoTest) for the prediction of liver steatosis Comp. Hepatol. 2005, 4, 10
29. Poynard, T.; Ratziu, V.; Charlotte, F.; Messous, D.; Munteanu, M.; Imbert-Bismut, F.; Massard, J.; Bonyhay, L.; Tahiri, M.; Thabut, D.; Cadranel, J. F.; Le Bail, B.; de Ledinghen, V. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease BMC Gastroenterol. 2006, 6, 34
30. Morra, R.; Munteanu, M.; Imbert-Bismut, F.; Messous, D.; Ratziu, V.; Poynard, T. FibroMAX: towards a new universal biomarker of liver disease? Expert Rev. Mol. Diagn. 2007, 7 (5) 481-90
31. Guha, I. N.; Parkes, J.; Roderick, P.; Chattopadhyay, D.; Cross, R.; Harris, S.; Kaye, P.; Burt, A. D.; Ryder, S. D.; Aithal, G. P.; Day, C. P.; Rosenberg, W. M. Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers Hepatology 2008, 47 (2) 455-60
32. Guha, I. N.; Rosenberg, W. M. Noninvasive assessment of liver fibrosis: serum markers, imaging, and other modalities Clin. Liver Dis. 2008, 12 (4) 883-900
33. Nicholson, J. K.; Connelly, J.; Lindon, J. C.; Holmes, E. Metabonomics: a platform for studying drug toxicity and gene function Nat. Rev. Drug Discovery 2002, 1 (2) 153-61
34. Nicholson, J. K.; Lindon, J. C.; Holmes, E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data Xenobiotica 1999, 29 (11) 1181-9
35. Gowda, G. A.; Zhang, S.; Gu, H.; Asiago, V.; Shanaiah, N.; Raftery, D. Metabolomics-based methods for early disease diagnostics Expert Rev. Mol. Diagn. 2008, 8 (5) 617-33
36. Kaddurah-Daouk, R.; Kristal, B. S.; Weinshilboum, R. M. Metabolomics: a global biochemical approach to drug response and disease Annu. Rev. Pharmacol. Toxicol. 2008, 48, 653-83
37. Puri, P.; Wiest, M. M.; Cheung, O.; Mirshahi, F.; Sargeant, C.; Min, H. K.; Contos, M. J.; Sterling, R. K.; Fuchs, M.; Zhou, H.; Watkins, S. M.; Sanyal, A. J. The plasma lipidomic signature of nonalcoholic steatohepatitis Hepatology 2009, 50 (6) 1827-38
38. Heijne, W. H.; Kienhuis, A. S.; van Ommen, B.; Stierum, R. H.; Groten, J. P. Systems toxicology: applications of toxicogenomics, transcriptomics, proteomics and metabolomics in toxicology Expert Rev. Proteomics 2005, 2 (5) 767-80
39. Varela-Rey, M.; Embade, N.; Ariz, U.; Lu, S. C.; Mato, J. M.; Martinez-Chantar, M. L. Non-alcoholic steatohepatitis and animal models: understanding the human disease Int. J. Biochem. Cell Biol. 2009, 41 (5) 969-76
40. Ariz, U.; Mato, J. M.; Lu, S. C.; Martinez Chantar, M. L. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods in Molecular Biology; Humana Press: Totowa, NJ, 2010; Vol. 593, pp 109 - 36.
41. Martinez-Chantar, M. L.; Vazquez-Chantada, M.; Ariz, U.; Martinez, N.; Varela, M.; Luka, Z.; Capdevila, A.; Rodriguez, J.; Aransay, A. M.; Matthiesen, R.; Yang, H.; Calvisi, D. F.; Esteller, M.; Fraga, M.; Lu, S. C.; Wagner, C.; Mato, J. M. Loss of the glycine N-methyltransferase gene leads to steatosis and hepatocellular carcinoma in mice Hepatology 2008, 47 (4) 1191-9
42. Kotb, M.; Mudd, S. H.; Mato, J. M.; Geller, A. M.; Kredich, N. M.; Chou, J. Y.; Cantoni, G. L. Consensus nomenclature for the mammalian methionine adenosyltransferase genes and gene products Trends Genet 1997, 13 (2) 51-2
43. Avila, M. A.; Garcia-Trevijano, E. R.; Martinez-Chantar, M. L.; Latasa, M. U.; Perez-Mato, I.; Martinez-Cruz, L. A.; del Pino, M. M.; Corrales, F. J.; Mato, J. M. S-Adenosylmethionine revisited: its essential role in the regulation of liver function Alcohol 2002, 27 (3) 163-7
44. Corrales, F. J.; Perez-Mato, I.; Sanchez Del Pino, M. M.; Ruiz, F.; Castro, C.; Garcia-Trevijano, E. R.; Latasa, U.; Martinez-Chantar, M. L.; Martinez-Cruz, A.; Avila, M. A.; Mato, J. M. Regulation of mammalian liver methionine adenosyltransferase J. Nutr. 2002, 132 (8 Suppl) 2377S-81S
45. Martinez-Chantar, M. L.; Garcia-Trevijano, E. R.; Latasa, M. U.; Perez-Mato, I.; Sanchez del Pino, M. M.; Corrales, F. J.; Avila, M. A.; Mato, J. M. Importance of a deficiency in S-adenosyl-L-methionine synthesis in the pathogenesis of liver injury Am. J. Clin. Nutr. 2002, 76 (5) 1177S-82S
46. Finkelstein, J. D. Metabolic regulatory properties of S-adenosylmethionine and S-adenosylhomocysteine Clin. Chem. Lab. Med. 2007, 45 (12) 1694-9
47. Heady, J. E.; Kerr, S. J. Alteration of glycine N-methyltransferase activity in fetal, adult, and tumor tissues Cancer Res. 1975, 35 (3) 640-3
48. Chen, S. Y.; Lin, J. R.; Darbha, R.; Lin, P.; Liu, T. Y.; Chen, Y. M. Glycine N-methyltransferase tumor susceptibility gene in the benzo(a)pyrene-detoxification pathway Cancer Res. 2004, 64 (10) 3617-23
49. Luka, Z.; Capdevila, A.; Mato, J. M.; Wagner, C. A glycine N-methyltransferase knockout mouse model for humans with deficiency of this enzyme Transgenic Res. 2006, 15 (3) 393-7
50. Griffiths, W. J.; Karu, K.; Hornshaw, M.; Woffendin, G.; Wang, Y. Metabolomics and metabolite profiling: past heroes and future developments Eur. J. Mass Spectrom. (Chichester, England) 2007, 13 (1) 45-50
51. Burton, L.; Ivosev, G.; Tate, S.; Impey, G.; Wingate, J.; Bonner, R. Instrumental and experimental effects in LC-MS-based metabolomics J. Chromatogr., B: Analyt. Technol. Biomed. Life Sci. 2008, 871 (2) 227-35
52. Theodoridis, G. G. HG; Wilson, ID, LC-MS-based methodology for global metabolite profiling in metabonomics/metabolomics Trends Anal. Chem. 2008, 27 (3) 238-50
53. Bedair, M. S. L.W., Current and emerging mass-spectrometry technologies for metabolomics Trends Anal. Chem. 2008, 27 (3) 251-60
54. Wold, S, J. E.; Cocchi, M. 3D-QSAR in drug design, theory, methods, and applications; ESCOM Science: Lieden, 1993.
55. Jolliffe, I. T. Principal component analysis; Springer: New York, 2002.
56. Bylesoö, M. OPLS discriminant analysis: combining the stregths of PLS-DA and SIMCA classification J. Chemometrics 2006, 20, 341-51
57. Wiklund, S.; Johansson, E.; Sjostrom, L.; Mellerowicz, E. J.; Edlund, U.; Shockcor, J. P.; Gottfries, J.; Moritz, T.; Trygg, J. Visualization of GC/TOF-MS-based metabolomics data for identification of biochemically interesting compounds using OPLS class models Anal. Chem. 2008, 80 (1) 115-22
58. Brugger, B.; Erben, G.; Sandhoff, R.; Wieland, F. T.; Lehmann, W. D. Quantitative analysis of biological membrane lipids at the low picomole level by nano-electrospray ionization tandem mass spectrometry Proc. Natl. Acad. Sci. U.S.A. 1997, 94 (6) 2339-44
59. Khaselev, N.; Murphy, R. C. Electrospray ionization mass spectrometry of lysoglycerophosphocholine lipid subclasses J. Am. Soc. Mass Spectrom. 2000, 11 (4) 283-91
60. Han, X. G. R. W. Structural Determination of Lysophospholipid Regioisomers by Electrospray Ionization Tandem Mass Spectrometry J. Am. Chem. Soc. 1996, 118, 451-57
61. Houjou, T.; Yamatani, K.; Nakanishi, H.; Imagawa, M.; Shimizu, T.; Taguchi, R. Rapid and selective identification of molecular species in phosphatidylcholine and sphingomyelin by conditional neutral loss scanning and MS3 Rapid Commun. Mass Spectrom. 2004, 18 (24) 3123-30
62. Duce, A. M.; Ortiz, P.; Cabrero, C.; Mato, J. M. S-adenosyl-L-methionine synthetase and phospholipid methyltransferase are inhibited in human cirrhosis Hepatology 1988, 8 (1) 65-8
63. Kharbanda, K. K.; Mailliard, M. E.; Baldwin, C. R.; Beckenhauer, H. C.; Sorrell, M. F.; Tuma, D. J. Betaine attenuates alcoholic steatosis by restoring phosphatidylcholine generation via the phosphatidylethanolamine methyltransferase pathway J. Hepatol. 2007, 46 (2) 314-21
64. Ikura, Y.; Ohsawa, M.; Suekane, T.; Fukushima, H.; Itabe, H.; Jomura, H.; Nishiguchi, S.; Inoue, T.; Naruko, T.; Ehara, S.; Kawada, N.; Arakawa, T.; Ueda, M. Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression Hepatology 2006, 43 (3) 506-14
65. Li, Z.; Agellon, L. B.; Allen, T. M.; Umeda, M.; Jewell, L.; Mason, A.; Vance, D. E. The ratio of phosphatidylcholine to phosphatidylethanolamine influences membrane integrity and steatohepatitis Cell Metab. 2006, 3 (5) 321-31
66. Nanji, A. A.; Blank, D. Low serum creatine kinase activity in patients with alcoholic liver disease Clin. Chem. 1981, 27 (11) 1954
67. Malnick, S. D.; Bass, D. D.; Kaye, A. M.; Creatine kinase, B. B. a response marker in liver and other organs Hepatology 1994, 19 (1) 261
68. Vaubourdolle, M.; Chazouilleres, O.; Poupon, R.; Ballet, F.; Braunwald, J.; Legendre, C.; Baudin, B.; Kirn, A.; Giboudeau, J. Creatine kinase-BB: a marker of liver sinusoidal damage in ischemia-reperfusion Hepatology 1993, 17 (3) 423-8
69. Gentile, C. L.; Pagliassotti, M. J. The role of fatty acids in the development and progression of nonalcoholic fatty liver disease J. Nutr. Biochem. 2008, 19 (9) 567-76
70. Puri, P.; Baillie, R. A.; Wiest, M. M.; Mirshahi, F.; Choudhury, J.; Cheung, O.; Sargeant, C.; Contos, M. J.; Sanyal, A. J. A lipidomic analysis of nonalcoholic fatty liver disease Hepatology 2007, 46 (4) 1081-90
71. Kotronen, A.; Seppanen-Laakso, T.; Westerbacka, J.; Kiviluoto, T.; Arola, J.; Ruskeepaa, A. L.; Oresic, M.; Yki-Jarvinen, H. Hepatic stearoyl-CoA desaturase (SCD)-1 activity and diacylglycerol but not ceramide concentrations are increased in the nonalcoholic human fatty liver Diabetes 2009, 58 (1) 203-8
72. Bass, N. M. Lipidomic dissection of nonalcoholic steatohepatitis: moving beyond foie gras to fat traffic Hepatology 2010, 51 (1) 4-7
73. Kunos, G.; Osei-Hyiaman, D. Endocannabinoids and liver disease. IV. Endocannabinoid involvement in obesity and hepatic steatosis Am. J. Physiol. Gastrointest. Liver Physiol. 2008, 294 (5) G1101-4
74. Six, D. A.; Dennis, E. A. The expanding superfamily of phospholipase A(2) enzymes: classification and characterization Biochim. Biophys. Acta 2000, 1488 (1-2) 1-19
75. Kudo, I.; Murakami, M. Phospholipase A2 enzymes Prostaglandins Other Lipid Mediat. 2002, 68-69, 3-58
76. Leslie, C. C.; Voelker, D. R.; Channon, J. Y.; Wall, M. M.; Zelarney, P. T. Properties and purification of an arachidonoyl-hydrolyzing phospholipase A2 from a macrophage cell line, RAW 264.7 Biochim. Biophys. Acta 1988, 963 (3) 476-92
77. Clark, J. D.; Lin, L. L.; Kriz, R. W.; Ramesha, C. S.; Sultzman, L. A.; Lin, A. Y.; Milona, N.; Knopf, J. L. A novel arachidonic acid-selective cytosolic PLA2 contains a Ca(2+)-dependent translocation domain with homology to PKC and GAP Cell 1991, 65 (6) 1043-51
78. Schievella, A. R.; Regier, M. K.; Smith, W. L.; Lin, L. L. Calcium-mediated translocation of cytosolic phospholipase A2 to the nuclear envelope and endoplasmic reticulum J. Biol. Chem. 1995, 270 (51) 30749-54
79. Pawliczak, R.; Logun, C.; Madara, P.; Lawrence, M.; Woszczek, G.; Ptasinska, A.; Kowalski, M. L.; Wu, T.; Shelhamer, J. H. Cytosolic phospholipase A2 Group IValpha but not secreted phospholipase A2 Group IIA, V or X induces interleukin-8 and cyclooxygenase-2 gene and protein expression through peroxisome proliferator-activated receptors gamma 1 and 2 in human lung cells J. Biol. Chem. 2004, 279 (47) 48550-61
80. Leslie, C. C. Regulation of the specific release of arachidonic acid by cytosolic phospholipase A2 Prostaglandins Leukot. Essent. Fatty Acids 2004, 70 (4) 373-6
81. Hirabayashi, T.; Murayama, T.; Shimizu, T. Regulatory mechanism and physiological role of cytosolic phospholipase A2 Biol. Pharm. Bull. 2004, 27 (8) 1168-73
82. Goetzl, E. J. Pleiotypic mechanisms of cellular responses to biologically active lysophospholipids Prostaglandins Other Lipid Mediat. 2001, 64 (1-4) 11-20
83. Kita, T. K.; n. Ishii, K.; Horiuchi, h.; Arai, H.; Yokode, M. Oxidized LDL and expression of monocyte adhesion molecules Diabetes Res. Clin. Pract. 1999, 45 (2-3) 123-26
84. Yang, L.; Xiong, A.; He, Y.; Wang, Z.; Wang, C.; Li, W.; Hu, Z. Bile acids metabonomic study on the CCl4- and alpha-naphthylisothiocyanate-induced animal models: quantitative analysis of 22 bile acids by ultraperformance liquid chromatography-mass spectrometry Chem. Res. Toxicol. 2008, 21 (12) 2280-8
85. Monte, M. J.; Marin, J. J.; Antelo, A.; Vazquez-Tato, J. Bile acids: chemistry, physiology, and pathophysiology World J. Gastroenterol. 2009, 15 (7) 804-16
86. Perez, M. J.; Briz, O. Bile-acid-induced cell injury and protection World J. Gastroenterol. 2009, 15 (14) 1677-89
87. Gilat, T.; Leikin-Frenkel, A.; Goldiner, I.; Juhel, C.; Lafont, H.; Gobbi, D.; Konikoff, F. M. Prevention of diet-induced fatty liver in experimental animals by the oral administration of a fatty acid bile acid conjugate (FABAC) Hepatology 2003, 38 (2) 436-42
88. Kobayashi, N.; Katsumata, H.; Uto, Y.; Goto, J.; Niwa, T.; Kobayashi, K.; Mizuuchi, Y. A monoclonal antibody-based enzyme-linked immunosorbent assay of glycolithocholic acid sulfate in human urine for liver function test Steroids 2002, 67 (10) 827-33
89. Mari, M.; Colell, A.; Morales, A.; Paneda, C.; Varela-Nieto, I.; Garcia-Ruiz, C.; Fernandez-Checa, J. C. Acidic sphingomyelinase downregulates the liver-specific methionine adenosyltransferase 1A, contributing to tumor necrosis factor-induced lethal hepatitis J. Clin. Invest. 2004, 113 (6) 895-904
90. Mari, M.; Fernandez-Checa, J. C. Sphingolipid signalling and liver diseases Liver Int. 2007, 27 (4) 440-50
91. Morales, A.; Lee, H.; Goni, F. M.; Kolesnick, R.; Fernandez-Checa, J. C. Sphingolipids and cell death Apoptosis 2007, 12 (5) 923-39
92. Engelmann, B. Plasmalogens: targets for oxidants and major lipophilic antioxidants Biochem. Soc. Trans. 2004, 32 (Pt 1) 147-50
93. Zoeller, R. A.; Lake, A. C.; Nagan, N.; Gaposchkin, D. P.; Legner, M. A.; Lieberthal, W. Plasmalogens as endogenous antioxidants: somatic cell mutants reveal the importance of the vinyl ether Biochem. J. 1999, 338 (Pt 3) 769-76
94. Tominaga, T.; Suzuki, H.; Mizuno, H.; Kouno, M.; Suzuki, M.; Kato, Y.; Sato, A.; Okabe, K.; Miyashita, M. Clinical significance of measuring plasma concentrations of glutamine and glutamate in alcoholic liver diseases Alcohol Alcohol Suppl. 1993, 1A, 103-9
95. Xie, Z.; Li, H.; Wang, K.; Lin, J.; Wang, Q.; Zhao, G.; Jia, W.; Zhang, Q. Analysis of transcriptome and metabolome profiles alterations in fatty liver induced by high-fat diet in rat Metabolism 2010, 59 (4) 554-60